猪胆酸

Hyocholic acid

	产品编号	CFN91626
	CAS编号	547-75-1
	分子式 = 分子量	C₂₄H₄₀O₅ = 408.6
	产品纯度	>=98%
	物理属性	Powder
	化合物类型	Steroids
	植物来源
ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用

提供自定义包装

产品名称	产品编号	CAS编号	包装	QQ客服
猪胆酸	CFN91626	547-75-1	1mg	QQ客服：3257982914
猪胆酸	CFN91626	547-75-1	5mg	QQ客服：3257982914
猪胆酸	CFN91626	547-75-1	10mg	QQ客服：3257982914
猪胆酸	CFN91626	547-75-1	20mg	QQ客服：3257982914

存储与注意事项

1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。通常，这些可用于长达两周。使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

3. 需要更多关于溶解度，使用和处理的建议？请发送电子邮件至：service@chemfaces.com

订购流程

1. 在线订购

请联系我们QQ客服

2. 电话订购

请拨打电话：
027-84237683 或 027-84237783

3. 邮件或传真订购

发送电子邮件到: manager@chemfaces.com 或
发送传真到：027-84254680

提供订购信息

为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。

1. 产品编号（CAS No.或产品名称）

2. 发货地址

3. 联系方法 (联系人，电话）

4. 开票抬头 (如果需要发票的客户）

5. 发票地址（发货地址与发票地址不同）

发货时间

1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。

Description:

Hyocholic acid(HCA) upregulates GLP-1 production and secretion in enteroendocrine cells and improves glucose homeostasis. Hyocholic acid has the effect of preventing and dissolving gallstones.

In vitro:

Hepatol Commun . 2021 Dec;5(12):2035-2051.

Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis[Pubmed: 34558841]

Accumulation of cytotoxic bile acids (BAs) during cholestasis can result in liver failure. Glucuronidation, a phase II metabolism pathway responsible for BA detoxification, is regulated by peroxisome proliferator-activated receptor alpha (PPARα). This study investigates the efficacy of adjunct fenofibrate therapy to up-regulate BA-glucuronidation and reduce serum BA toxicity during cholestasis. Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1.5 times the upper limit of normal, received additional fenofibrate (145-160 mg/day) as standard of care. Serum BA and BA-glucuronide concentrations were measured by liquid chromatography-mass spectrometry. Combination therapy with fenofibrate significantly decreased elevated serum ALP (-76%, P < 0.001), aspartate transaminase, alanine aminotransferase, bilirubin, total serum BAs (-54%), and increased serum BA-glucuronides (+2.1-fold, P < 0.01) versus ursodiol monotherapy. The major serum BA-glucuronides that were favorably altered following adjunct fenofibrate include hyodeoxycholic acid-6G (+3.7-fold, P < 0.01), hyocholic acid-6G (+2.6-fold, P < 0.05), chenodeoxycholic acid (CDCA)-3G (-36%), and lithocholic acid (LCA)-3G (-42%) versus ursodiol monotherapy. Fenofibrate also up-regulated the expression of uridine 5'-diphospho-glucuronosyltransferases and multidrug resistance-associated protein 3 messenger RNA in primary human hepatocytes. Pearson's correlation coefficients identified strong associations between serum ALP and metabolic ratios of CDCA-3G (r2 = 0.62, P < 0.0001), deoxycholic acid (DCA)-3G (r2 = 0.48, P < 0.0001), and LCA-3G (r2 = 0.40, P < 0.001), in ursodiol monotherapy versus control. Receiver operating characteristic analysis identified serum BA-glucuronides as measures of response to therapy. Conclusion: Fenofibrate favorably alters major serum BA-glucuronides, which correlate with reduced serum ALP levels and improved outcomes. A PPARα-mediated anti-cholestatic mechanism is involved in detoxifying serum BAs in patients with PBC and PSC who have an incomplete response on ursodiol monotherapy and receive adjunct fenofibrate. Serum BA-glucuronides may serve as a noninvasive measure of treatment response in PBC and PSC.

In vivo:

Cell Metab . 2021 Apr 6;33(4):791-803.

Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism[Pubmed: 33338411]

Hyocholic acid (HCA) and its derivatives are found in trace amounts in human blood but constitute approximately 76% of the bile acid (BA) pool in pigs, a species known for its exceptional resistance to type 2 diabetes. Here, we show that BA depletion in pigs suppressed secretion of glucagon-like peptide-1 (GLP-1) and increased blood glucose levels. HCA administration in diabetic mouse models improved serum fasting GLP-1 secretion and glucose homeostasis to a greater extent than tauroursodeoxycholic acid. HCA upregulated GLP-1 production and secretion in enteroendocrine cells via simultaneously activating G-protein-coupled BA receptor, TGR5, and inhibiting farnesoid X receptor (FXR), a unique mechanism that is not found in other BA species. We verified the findings in TGR5 knockout, intestinal FXR activation, and GLP-1 receptor inhibition mouse models. Finally, we confirmed in a clinical cohort, that lower serum concentrations of HCA species were associated with diabetes and closely related to glycemic markers.

Can J Physiol Pharmacol . 1988 Aug;66(8):1028-1034.

Effect of hyocholic acid on the prevention and dissolution of biliary cholesterol crystals in mice[Pubmed: 3179836]

Gallstone prevention and dissolution were studied in a mouse model of cholesterol cholelithiasis using hyocholic acid (3 alpha, 6 alpha, 7 alpha-trihydroxy-5 beta-cholanic acid). Addition of hyocholic acid, 0.1 or 0.3%, in the lithogenic diet (1% cholesterol + 0.5% cholic acid) prevented the formation of cholesterol monohydrate crystals in 70 and 90% of cases, respectively. On the other hand, chow diet supplemented with 0.1 or 0.3% hyocholic acid dissolved cholesterol crystals in lithiasic mice in, respectively, 80 and 100% of cases within 12 days. In both protocols, biles were largely supersaturated with cholesterol; lecithin-cholesterol lamellar liquid crystals were responsible for the transport of the excess cholesterol content. The percentage of hydrophilic bile salts (hyocholic acid, hyodeoxycholic acid, beta-muricholic acid) in bile, although moderate (15-50% of total bile salts), appears to induce such liquid crystalline dispersion. This study demonstrates that the balance between hydrophilic and hydrophobic bile salts plays a major role in the prevention and dissolution of cholesterol crystals. It is also shown that the desaturation of biliary cholesterol is not a prerequisite for gallstone dissolution.

产品名称	产品编号	CAS编号	分子式 = 分子量	位单	联系QQ
甘氨脱氧胆酸; Glycodeoxycholic acid	CFN96947	360-65-6	C₂₆H₄₃NO₅ = 449.63	20mg	QQ客服：2159513211
甘氨熊去氧胆酸; Glycoursodeoxycholic acid	CFN89075	64480-66-6	C₂₆H₄₃NO₅ = 449.63	20mg	QQ客服：3257982914
牛磺胆酸; Taurocholic acid	CFN96646	81-24-3	C₂₆H₄₅NO₇S = 515.70	5mg	QQ客服：215959384
牛磺熊去氧胆酸 ; Tauroursodeoxycholic acid	CFN96645	14605-22-2	C₂₆H₄₅NO₆S = 499.70	5mg	QQ客服：3257982914
牛磺鹅去氧胆酸钠; Sodium taurochenodeoxycholate	CFN80241	6009-98-9	C₂₆H₄₄NNaO₆S = 521.68	5mg	QQ客服：1457312923
熊去氧胆酸; Ursodeoxycholic acid	CFN96464	128-13-2	C₂₄H₄₀O₄ = 392.58	20mg	QQ客服：2056216494
鹅去氧胆酸；鹅脱氧胆酸; Chenodeoxycholic acid	CFN90478	474-25-9	C₂₄H₄₀O₄ = 392.57	20mg	QQ客服：2056216494
胆酸; Cholic acid	CFN99796	81-25-4	C₂₂H₄₀O₅ = 408.57	20mg	QQ客服：215959384
猪胆酸; Hyocholic acid	CFN91626	547-75-1	C₂₄H₄₀O₅ = 408.6	5mg	QQ客服：215959384
去氧胆酸; Deoxycholic acid	CFN99798	83-44-3	C₂₄H₄₀O₄ = 392.57	20mg	QQ客服：1457312923

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.4474 mL	12.2369 mL	24.4738 mL	48.9476 mL	61.1845 mL
5 mM	0.4895 mL	2.4474 mL	4.8948 mL	9.7895 mL	12.2369 mL
10 mM	0.2447 mL	1.2237 mL	2.4474 mL	4.8948 mL	6.1185 mL
50 mM	0.0489 mL	0.2447 mL	0.4895 mL	0.979 mL	1.2237 mL
100 mM	0.0245 mL	0.1224 mL	0.2447 mL	0.4895 mL	0.6118 mL

猪胆酸

Hyocholic acid

信息支持

联系方式